The VASCULAID consortium is delighted to share an important milestone in the progress of our clinical research activities. The first patients have now been successfully included in the prospective study at the Amsterdam site, marking the transition from preparation to active clinical enrolment within our six participating clinical centres. This milestone demonstrates the project’s steady progress toward validating VASculaid’s technology in real-world clinical settings.
Our very first participant was a patient diagnosed with an abdominal aortic aneurysm (AAA), symbolising the core mission of VASculaid: to harness the power of artificial intelligence to improve the management and outcomes of complex vascular diseases. Since then, four additional patients have joined the study, and the recruitment process is steadily gaining momentum across participating centres.
This progress reflects the tremendous effort and collaboration within the VASculaid clinical and research teams. We would like to acknowledge the outstanding efforts of Julia, Luc, and Tim, whose hard work and coordination made the first patient inclusions possible. Their dedication and teamwork reflect the collaborative spirit at the heart of the VASculaid project.
We also wish to acknowledge the unwavering leadership and vision of Prof. Dr. Kak Khee Yeung, whose commitment to advancing vascular innovation continues to inspire the entire team. Her guidance has been instrumental in achieving this early success and in setting the foundation for the next phases of our clinical journey.
The VASCULAID consortium looks forward to continuing recruitment and expanding participation in the months ahead, bringing us closer to our shared goal of improving patient outcomes through data-driven vascular care.